Pamela Vo
VP, HEOR
Expertise:
Pamela Vo brings over 18 years of HEOR experience in the pharmaceutical industry, showcasing a history of strategically translating ideas into impactful outcomes. She boasts a proven track record of peer-reviewed publications, significant achievements in market access and reimbursement, regulatory approvals, and successful clinical product adoption. Her expertise spans multiple therapeutic areas across the United States and international landscapes. Notably, Vo’s most recent position was as the Global HEOR & Access Evidence Executive Director at Novartis.
Prior to her tenure at Novartis, Vo held roles such as Worldwide HEOR Director within the Global Patient Access division at Novartis, and various leadership positions at Lundbeck and Abbott/AbbVie, where she managed diverse healthcare portfolios.
Vo holds a Doctor of Pharmacy degree and a Master of Pharmacoeconomics and Policy degree. She recently obtained certification in Immuno-Oncology from Harvard Medical School HMX Pro. Currently based in Switzerland, Vo looks forward to expanding EVERSANA’s scientific expertise across Europe, the U.S., and beyond.
Articles by Pamela Vo
Unveiling Challenges: Analyzing Stakeholder Feedback on the EU Joint Clinical Assessment Implementation Act and Its Impact on the Latest Draft
On March 5, 2024, the draft Implementation Act (IA) for Joint Clinical Assessment (JCA) for medicinal products was released for public comments. The intent of the draft IA was to provide more granular details on the JCA process within the framework of the Health Technology Assessment Regulation (HTAR). By the April 2, 2024, deadline, 129 responses by various stakeholders were received. The responses were categorized by organizational types, which included: Company/Business, Business Associations, Academic/Research Institutions, Non-governmental Organization (NGO), EU/Non-EU Citizens, Trade, Public Authority, Environmental Organization and Other. The Company/Business (21%) and Business Associations (19%) together comprised 40% of the responses. Among the respondents from the Company/Business stakeholder, the No. 1 […]
Decoding EMA’s Blueprint on Real-World Evidence
The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from RWD analysis, within the scope of regulatory decision-making. It details the types of studies that can be conducted, how the EMA can pinpoint optimal resources to address research inquiries, and the procedure for requesting RWD studies. Here are the three pivotal findings from the EMA report on RWE: RWE Generation Pathways: The EMA has delineated three principal avenues for RWE production: the Data Analysis and Real World Interrogation Network (DARWIN EU), in-house electronic health […]